Hypoxia and prognosis: The oxygen tension mounts

Frontiers in Bioscience

Volumn 12, Issue 9, 2007, Pages 3502-3518

  Wilson, George David ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Cancer; Hypoxia; Hypoxia associated proteins; Nitroimidazole; NMR; Oxygen electrode; PET; Prognosis; Radiotherapy

Indexed keywords

OXYGEN;

ANOXIA; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS; REVIEW;

ANOXIA; HUMANS; NEOPLASMS; OXYGEN; PROGNOSIS;

EID: 34347210303     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2330     Document Type: Review

References (146)

1. Thomlinson, R. H. & L. H. Gray: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer, 9, 539-49 (1955)
2. Hockel, M., K. Schlenger, C. Knoop & P. Vaupel: Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res, 51, 6098-102 (1991)
3. Vaupel, P., K. Schlenger, C. Knoop & M. Hockel: Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res, 51, 3316-22 (1991)
4. Cline, J. M., D. E. Thrall, R. L. Page, A. J. Franko & J. A. Raleigh: Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. Br J Cancer, 62, 925-31 (1990)
5. Urtasun, R. C., J. D. Chapman, J. A. Raleigh, A. J. Franko & C. J. Koch: Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys, 12, 1263-7 (1986) (Pubitemid 16055899)
6. Vaupel, P., A. Mayer & M. Hockel: Tumor hypoxia and malignant progression. Methods Enzymol, 381, 335-54 (2004) (Pubitemid 38401518)
7. Folkman, J.: Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6 (1971)
8. Folkman, J.: Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8 (2002)
9. Jain, R. K.: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol, 29, 3-9 (2002)
10. Konerding, M. A., A. J. Miodonski & A. Lametschwandtner: Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc, 9, 1233-43; discussion 1243-4 (1995)
11. Vaupel, P. & A. Mayer: Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol, 12, 5-10 (2005) (Pubitemid 40487494)
12. Freyer, J. P.: Rates of oxygen consumption for proliferating and quiescent cells isolated from multicellular tumor spheroids. Adv Exp Med Biol, 345, 335-42 (1994) (Pubitemid 24145768)
13. Moeller, B. J., Y. Cao, Z. Vujaskovic, C. Y. Li, Z. A. Haroon & M. W. Dewhirst: The relationship between hypoxia and angiogenesis. Semin Radiat Oncol, 14, 215-21 (2004) (Pubitemid 38903225)
14. Brizel, D. M., G. S. Sibley, L. R. Prosnitz, R. L. Scher & M. W. Dewhirst: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys, 38, 285-9 (1997) (Pubitemid 27318643)
15. Fyles, A. W., M. Milosevic, R. Wong, M. C. Kavanagh, M. Pintilie, A. Sun, W. Chapman, W. Levin, L. Manchul, T. J. Keane & R. P. Hill: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol, 48, 149-56. (1998) (Pubitemid 28423786)
16. Hockel, M., C. Knoop, K. Schlenger, B. Vorndran, E. Baussmann, M. Mitze, P. G. Knapstein & P. Vaupel: Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol, 26, 45-50 (1993) (Pubitemid 23063609)
17. Knocke, T. H., H. D. Weitmann, H. J. Feldmann, E. Selzer & R. Potter: Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol, 53, 99-104. (1999)
18. Nordsmark, M. & J. Overgaard: A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol, 57, 39-43. (2000)
19. Stone, H. B., J. M. Brown, T. L. Phillips & R. M. Sutherland: Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res, 136, 422-34 (1993) (Pubitemid 2038893)
20. Olive, P. L., J. P. Banath & C. Aquino-Parsons: Measuring hypoxia in solid tumours-is there a gold standard? Acta Oncol, 40, 917-23 (2001) (Pubitemid 34098477)
21. Toma-Dasu, L., A. Waites, A. Dasu & J. Denekamp: Theoretical simulation of oxygen tension measurement in tissues using a microelectrode: I. The response function of the electrode. Physiol Meas, 22, 713-25 (2001) (Pubitemid 33104657)
22. Diergarten, T., P. Martirosian, R. Kottke, U. Vogel, A. Stenzl, C. D. Claussen & H. P. Schlemmer: Functional characterization of prostate cancer by integrated magnetic resonance imaging and oxygenation changes during carbogen breathing. Invest Radiol, 40, 102-9 (2005) (Pubitemid 40144416)
23. Zhong, J., W. C. Kwok & P. Okunieff: fMRI for monitoring dynamic changes in tissue oxygenation/blood flow: potential applications for tumor response to carbogen treatment. Adv Exp Med Biol, 530, 449-59 (2003) (Pubitemid 37352384)
24. Sotak, C. H., P. S. Hees, H. N. Huang, M. H. Hung, C. G. Krespan & S. Raynolds: A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn Reson Med, 29, 188-95 (1993) (Pubitemid 23078511)
25. van der Sanden, B. P., A. Heerschap, A. W. Simonetti, P. F. Rijken, H. P. Peters, G. Stuben & A. J. van der Kogel: Characterization and validation of noninvasive oxygen tension measurements in human glioma xenografts by 19F-MR relaxometry. Int J Radiat Oncol Biol Phys, 44, 649-58 (1999) (Pubitemid 29258441)
26. Mason, R. P., S. Hunjan, A. Constantinescu, Y. Song, D. Zhao, E. W. Hahn, P. P. Antich & P. Peschke: Tumor oximetry: comparison of 19F MR EPI and electrodes. Adv Exp Med Biol, 530, 19-27 (2003) (Pubitemid 37352345)
27. Mason, R. P., A. Constantinescu, S. Hunjan, D. Le, E. W. Hahn, P. P. Antich, C. Blum & P. Peschke: Regional tumor oxygenation and measurement of dynamic changes. Radiat Res, 152, 239-49 (1999) (Pubitemid 29413659)
28. Kim, J. G., D. Zhao, Y. Song, A. Constantinescu, R. P. Mason & H. Liu: Interplay of tumor vascular oxygenation and tumor pO2 observed using near-infrared spectroscopy, an oxygen needle electrode, and 19F MR pO2 mapping. J Biomed Opt, 8, 53-62 (2003)
29. Swartz, H. M., N. Khan, J. Buckey, R. Comi, L. Gould, O. Grinberg, A. Hartford, H. Hopf, H. Hou, E. Hug, A. Iwasaki, P. Lesniewski, I. Salikhov & T. Walczak: Clinical applications of EPR: overview and perspectives. NMR Biomed, 17, 335-51 (2004) (Pubitemid 39255841)
30. Seddon, B. M., D. J. Honess, B. Vojnovic, G. M. Tozer & P. Workman: Measurement of tumor oxygenation: in vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res, 155, 837-46 (2001) (Pubitemid 32494611)
31. Young, W. K., B. Vojnovic & P. Wardman: Measurement of oxygen tension in tumours by timeresolved fluorescence. Br J Cancer Suppl, 27, S256-9 (1996) (Pubitemid 26237973)
32. Rischin, D., R. J. Hicks, R. Fisher, D. Binns, J. Corry, S. Porceddu & L. J. Peters: Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol, 24, 2098-104 (2006) (Pubitemid 46622121)
33. Thorwarth, D., S. M. Eschmann, J. Scheiderbauer, F. Paulsen & M. Alber: Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer, 5, 152 (2005)
34. Arteel, G. E., R. G. Thurman, J. M. Yates & J. A. Raleigh: Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer, 72, 889-95 (1995)
35. Raleigh, J. A., S. C. Chou, E. L. Bono, D. E. Thrall & M. A. Varia: Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys, 49, 569-74 (2001) (Pubitemid 32123612)
36. Evans, S. M., D. Fraker, S. M. Hahn, K. Gleason, W. T. Jenkins, K. Jenkins, W. T. Hwang, P. Zhang, R. Mick & C. J. Koch: EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys, 64, 922-7 (2006) (Pubitemid 43183594)
37. Lord, E. M., L. Harwell & C. J. Koch: Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res, 53, 5721-6 (1993) (Pubitemid 23360277)
38. Wykoff, C. C., C. W. Pugh, A. L. Harris, P. H. Maxwell & P. J. Ratcliffe: The HIF pathway: implications for patterns of gene expression in cancer. Novartis Found Symp, 240, 212-25; discussion 225-31 (2001) (Pubitemid 33603789)
39. Bardos, J. I. & M. Ashcroft: Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays, 26, 262-9 (2004) (Pubitemid 38325667)
40. Haddad, J. J. & H. L. Harb: Cytokines and the regulation of hypoxia-inducible factor (HIF)-1alpha. Int Immunopharmacol, 5, 461-83 (2005) (Pubitemid 40430755)
41. Zhou, J. & B. Brune: NO and transcriptional regulation: from signaling to death. Toxicology, 208, 223-33 (2005) (Pubitemid 40192534)
42. Vordermark, D. & J. M. Brown: Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol, 179, 801-11 (2003) (Pubitemid 37509467)
43. Overgaard, J. & M. R. Horsman: Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. Semin Radiat Oncol, 6, 10-21 (1996) (Pubitemid 26029371)
44. Saunders, M. & S. Dische: Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer Suppl, 27, S271-8 (1996) (Pubitemid 26237977)
45. Denekamp, J. & J. F. Fowler: ARCON-current status: summary of a workshop on preclinical and clinical studies. Acta Oncol, 36, 517-25 (1997) (Pubitemid 27372146)
46. Kaanders, J. H., J. Bussink & A. J. van der Kogel: ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol, 3, 728-37 (2002) (Pubitemid 35446742)
47. Janssen, H. L., F. J. Hoebers, D. Sprong, L. Goethals, K. J. Williams, I. J. Stratford, K. M. Haustermans, A. J. Balm & A. C. Begg: Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol, 70, 91-7 (2004) (Pubitemid 38177168)
48. Denekamp, J. & A. Dasu: Inducible repair and the two forms of tumour hypoxia-time for a paradigm shift. Acta Oncol, 38, 903-18 (1999)
49. Hall, E. J., J. S. Bedford & R. Oliver: Extreme hypoxia; its effect on the survival of mammalian cells irradiated at high and low dose-rates. Br J Radiol, 39, 302-7 (1966)
50. Ling, C. C., E. Robinson & D. C. Shrieve: Repair of radiation induced damage-dependence on oxygen and energy status. Int J Radiat Oncol Biol Phys, 15, 1179-86 (1988) (Pubitemid 18265356)
51. Zolzer, F. & C. Streffer: Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys, 54, 910-20 (2002)
52. Pigott, K. H., S. A. Hill, D. J. Chaplin & M. I. Saunders: Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol, 40, 45-50 (1996) (Pubitemid 26246264)
53. Wouters, B. G. & J. M. Brown: Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res, 147, 541-50 (1997) (Pubitemid 27204090)
54. Evans, S. M. & C. J. Koch: Prognostic significance of tumor oxygenation in humans. Cancer Lett, 195, 1-16 (2003) (Pubitemid 36603331)
55. Kaanders, J. H., K. I. Wijffels, H. A. Marres, A. S. Ljungkvist, L. A. Pop, F. J. van den Hoogen, P. C. de Wilde, J. Bussink, J. A. Raleigh & A. J. van der Kogel: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res, 62, 7066-74 (2002) (Pubitemid 35424102)
56. Toma-Dasu, I., A. Dasu, A. Waites & J. Denekamp: Computer simulation of oxygen microelectrode measurements in tissues. Adv Exp Med Biol, 510, 157-61 (2003) (Pubitemid 36307770)
57. Hockel, M. & P. Vaupel: Biological consequences of tumor hypoxia. Semin Oncol, 28, 36-41 (2001) (Pubitemid 32522236)
58. Vaupel, P. & M. Hockel: Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int J Oncol, 17, 869-79 (2000)
59. Vaupel, P., D. K. Kelleher & M. Hockel: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol, 28, 29-35 (2001) (Pubitemid 32522235)
60. Vaupel, P. & L. Harrison: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist, 9 Suppl 5, 4-9 (2004) (Pubitemid 39658340)
61. Hoskin, P. J., A. Sibtain, F. M. Daley, M. I. Saunders & G. D. Wilson: The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol, 72, 159-68 (2004) (Pubitemid 39024591)
62. Hoogsteen, I. J., H. A. Marres, K. I. Wijffels, P. F. Rijken, J. P. Peters, F. J. van den Hoogen, E. Oosterwijk, A. J. van der Kogel & J. H. Kaanders: Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res, 11, 97-106 (2005) (Pubitemid 40075783)
63. Jankovic, B., C. Aquino-Parsons, J. A. Raleigh, E. J. Stanbridge, R. E. Durand, J. P. Banath, S. H. MacPhail & P. L. Olive: Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom, 70, 45-55 (2006)
64. Nordsmark, M., J. Loncaster, C. Aquino-Parsons, S. C. Chou, M. Ladekarl, H. Havsteen, J. C. Lindegaard, S. E. Davidson, M. Varia, C. West, R. Hunter, J. Overgaard & J. A. Raleigh: Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol, 67, 35-44 (2003) (Pubitemid 36570438)
65. Airley, R., J. Loncaster, S. Davidson, M. Bromley, S. Roberts, A. Patterson, R. Hunter, I. Stratford & C. West: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res, 7, 928-34 (2001) (Pubitemid 32708731)
66. Hedley, D., M. Pintilie, J. Woo, A. Morrison, D. Birle, A. Fyles, M. Milosevic & R. Hill: Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res, 9, 5666-74 (2003) (Pubitemid 37499489)
67. Hutchison, G. J., H. R. Valentine, J. A. Loncaster, S. E. Davidson, R. D. Hunter, S. A. Roberts, A. L. Harris, I. J. Stratford, P. M. Price & C. M. West: Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res, 10, 8405-12 (2004) (Pubitemid 40053403)
68. Loncaster, J. A., A. L. Harris, S. E. Davidson, J. P. Logue, R. D. Hunter, C. C. Wycoff, J. Pastorek, P. J. Ratcliffe, I. J. Stratford & C. M. West: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res, 61, 6394-9 (2001) (Pubitemid 32783244)
69. Olive, P. L., C. Aquino-Parsons, S. H. MacPhail, S. Y. Liao, J. A. Raleigh, M. I. Lerman & E. J. Stanbridge: Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res, 61, 8924-9 (2001) (Pubitemid 34013910)
70. Kaluz, S., M. Kaluzova, A. Chrastina, P. L. Olive, S. Pastorekova, J. Pastorek, M. I. Lerman & E. J. Stanbridge: Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res, 62, 4469-77 (2002) (Pubitemid 34827310)
71. Nordsmark, M., M. Overgaard & J. Overgaard: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol, 41, 31-9 (1996) (Pubitemid 26396294)
72. Nordsmark, M., S. M. Bentzen, V. Rudat, D. Brizel, E. Lartigau, P. Stadler, A. Becker, M. Adam, M. Molls, J. Dunst, D. J. Terris & J. Overgaard: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol, 77, 18-24 (2005) (Pubitemid 41503384)
73. Bussink, J., M. R. Stratford, A. J. van der Kogel, L. K. Folkes & J. H. Kaanders: Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiother Oncol, 63, 285-91 (2002) (Pubitemid 34874556)
74. Pastorekova, S., S. Parkkila, J. Pastorek & C. T. Supuran: Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem, 19, 199-229 (2004) (Pubitemid 39004275)
75. Svastova, E., A. Hulikova, M. Rafajova, M. Zat'ovicova, A. Gibadulinova, A. Casini, A. Cecchi, A. Scozzafava, C. T. Supuran, J. Pastorek & S. Pastorekova: Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett, 577, 439-45 (2004) (Pubitemid 39535327)
76. Ivanov, S., S. Y. Liao, A. Ivanova, A. Danilkovitch-Miagkova, N. Tarasova, G. Weirich, M. J. Merrill, M. A. Proescholdt, E. H. Oldfield, J. Lee, J. Zavada, A. Waheed, W. Sly, M. I. Lerman & E. J. Stanbridge: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol, 158, 905-19 (2001) (Pubitemid 32221783)
77. Wykoff, C. C., N. J. Beasley, P. H. Watson, K. J. Turner, J. Pastorek, A. Sibtain, G. D. Wilson, H. Turley, K. L. Talks, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe & A. L. Harris: Hypoxia-inducible expression of tumorassociated carbonic anhydrases. Cancer Res, 60, 7075-83 (2000) (Pubitemid 32059187)
78. Lal, A., H. Peters, B. St Croix, Z. A. Haroon, M. W. Dewhirst, R. L. Strausberg, J. H. Kaanders, A. J. van der Kogel & G. J. Riggins: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst, 93, 1337-43 (2001) (Pubitemid 32910575)
79. Koukourakis, M. I., A. Giatromanolaki, E. Sivridis, C. Simopoulos, H. Turley, K. Talks, K. C. Gatter & A. L. Harris: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys, 53, 1192-202 (2002) (Pubitemid 34787855)
80. Giatromanolaki, A., M. I. Koukourakis, E. Sivridis, J. Pastorek, C. C. Wykoff, K. C. Gatter & A. L. Harris: Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res, 61, 7992-8 (2001) (Pubitemid 33049392)
81. Hui, E. P., A. T. Chan, F. Pezzella, H. Turley, K. F. To, T. C. Poon, B. Zee, F. Mo, P. M. Teo, D. P. Huang, K. C. Gatter, P. J. Johnson & A. L. Harris: Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res, 8, 2595-604 (2002) (Pubitemid 34856346)
82. Koukourakis, M. I., S. M. Bentzen, A. Giatromanolaki, G. D. Wilson, F. M. Daley, M. I. Saunders, S. Dische, E. Sivridis & A. L. Harris: Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol, 24, 727-35 (2006) (Pubitemid 46622039)
83. De Schutter, H., W. Landuyt, E. Verbeken, L. Goethals, R. Hermans & S. Nuyts: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy+/-chemotherapy. BMC Cancer, 5, 42 (2005)
84. Swinson, D. E., G. Cox & K. J. O'Byrne: Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer, 91, 1301-7 (2004) (Pubitemid 39424791)
85. Simi, L., G. Venturini, F. Malentacchi, S. Gelmini, M. Andreani, A. Janni, S. Pastorekova, C. T. Supuran, M. Pazzagli & C. Orlando: Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. Lung Cancer, 52, 59-66 (2006) (Pubitemid 43340200)
86. Le, Q. T., E. Chen, A. Salim, H. Cao, C. S. Kong, R. Whyte, J. Donington, W. Cannon, H. Wakelee, R. Tibshirani, J. D. Mitchell, D. Richardson, K. J. O'Byrne, A. C. Koong & A. J. Giaccia: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res, 12, 1507-14 (2006)
87. Kim, S. J., Z. N. Rabbani, R. T. Vollmer, E. G. Schreiber, E. Oosterwijk, M. W. Dewhirst, Z. Vujaskovic & M. J. Kelley: Carbonic anhydrase IX in early-stage nonsmall cell lung cancer. Clin Cancer Res, 10, 7925-33 (2004) (Pubitemid 39587532)
88. Kim, S. J., Z. N. Rabbani, M. W. Dewhirst, Z. Vujaskovic, R. T. Vollmer, E. G. Schreiber, E. Oosterwijk & M. J. Kelley: Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer, 49, 325-35 (2005) (Pubitemid 41139145)
89. Hussain, S. A., D. H. Palmer, R. Ganesan, L. Hiller, J. Gregory, P. G. Murray, J. Pastorek, L. Young & N. D. James: Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep, 11, 1005-10 (2004)
90. Hoskin, P. J., A. Sibtain, F. M. Daley & G. D. Wilson: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer, 89, 1290-7 (2003) (Pubitemid 37363419)
91. Dorai, T., I. S. Sawczuk, J. Pastorek, P. H. Wiernik & J. P. Dutcher: The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer, 41, 2935-47 (2005) (Pubitemid 41713134)
92. Bui, M. H., H. Visapaa, D. Seligson, H. Kim, K. R. Han, Y. Huang, S. Horvath, E. J. Stanbridge, A. Palotie, R. A. Figlin & A. S. Belldegrun: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol, 171, 2461-6 (2004) (Pubitemid 38625515)
93. Bui, M. H., D. Seligson, K. R. Han, A. J. Pantuck, F. J. Dorey, Y. Huang, S. Horvath, B. C. Leibovich, S. Chopra, S. Y. Liao, E. Stanbridge, M. I. Lerman, A. Palotie, R. A. Figlin & A. S. Belldegrun: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res, 9, 802-11 (2003) (Pubitemid 36182618)
94. Span, P. N., J. Bussink, P. Manders, L. V. Beex & C. G. Sweep: Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer, 89, 271-6 (2003) (Pubitemid 36976315)
95. Chia, S. K., C. C. Wykoff, P. H. Watson, C. Han, R. D. Leek, J. Pastorek, K. C. Gatter, P. Ratcliffe & A. L. Harris: Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol, 19, 3660-8 (2001) (Pubitemid 32786278)
96. Maseide, K., R. A. Kandel, R. S. Bell, C. N. Catton, B. O'Sullivan, J. S. Wunder, M. Pintilie, D. Hedley & R. P. Hill: Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res, 10, 4464-71 (2004) (Pubitemid 38878890)
97. Haapasalo, J. A., K. M. Nordfors, M. Hilvo, I. J. Rantala, Y. Soini, A. K. Parkkila, S. Pastorekova, J. Pastorek, S. M. Parkkila & H. K. Haapasalo: Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res, 12, 473-7 (2006) (Pubitemid 43166138)
98. Driessen, A., W. Landuyt, S. Pastorekova, J. Moons, L. Goethals, K. Haustermans, P. Nafteux, F. Penninckx, K. Geboes, T. Lerut & N. Ectors: Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a proangiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg, 243, 334-40 (2006) (Pubitemid 43327764)
99. Mayer, A., M. Hockel & P. Vaupel: Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res, 11, 7220-5 (2005) (Pubitemid 41507678)
100. Mayer, A., M. Hockel, A. Wree & P. Vaupel: Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin Cancer Res, 11, 2768-73 (2005) (Pubitemid 40569479)
101. Mayer, A., A. Wree, M. Hockel, C. Leo, H. Pilch & P. Vaupel: Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res, 64, 5876-81 (2004) (Pubitemid 39095589)
102. Wood, I. S. & P. Trayhurn: Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr, 89, 3-9 (2003) (Pubitemid 36187532)
103. Medina, R. A. & G. I. Owen: Glucose transporters: expression, regulation and cancer. Biol Res, 35, 9-26 (2002) (Pubitemid 34661867)
104. Mineta, H., K. Miura, S. Takebayashi, K. Misawa, K. Araki, Y. Misawa & Y. Ueda: Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res, 22, 3489-94 (2002) (Pubitemid 36132817)
105. Kunkel, M., T. E. Reichert, P. Benz, H. A. Lehr, J. H. Jeong, S. Wieand, P. Bartenstein, W. Wagner & T. L. Whiteside: Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer, 97, 1015-24 (2003) (Pubitemid 36173153)
106. Vleugel, M. M., A. E. Greijer, A. Shvarts, P. van der Groep, M. van Berkel, Y. Aarbodem, H. van Tinteren, A. L. Harris, P. J. van Diest & E. van der Wall: Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol, 58, 172-7 (2005) (Pubitemid 40193803)
107. Kang, S. S., Y. K. Chun, M. H. Hur, H. K. Lee, Y. J. Kim, S. R. Hong, J. H. Lee, S. G. Lee & Y. K. Park: Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res, 93, 1123-8 (2002) (Pubitemid 35314957)
108. Younes, M., R. W. Brown, M. Stephenson, M. Gondo & P. T. Cagle: Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer, 80, 1046-51 (1997) (Pubitemid 27427603)
109. Minami, K., Y. Saito, H. Imamura & A. Okamura: Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer, 38, 51-7 (2002) (Pubitemid 35299992)
110. Palit, V., R. M. Phillips, R. Puri, T. Shah & M. C. Bibby: Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep, 14, 909-13 (2005)
111. Younes, M., D. Juarez, L. V. Lechago & S. P. Lerner: Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res, 21, 575-8 (2001) (Pubitemid 32267574)
112. Kawamura, T., T. Kusakabe, T. Sugino, K. Watanabe, T. Fukuda, A. Nashimoto, K. Honma & T. Suzuki: Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer, 92, 634-41 (2001) (Pubitemid 32735200)
113. Tohma, T., S. Okazumi, H. Makino, A. Cho, R. Mochizuki, K. Shuto, H. Kudo, K. Matsubara, H. Gunji, H. Matsubara & T. Ochiai: Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus, 18, 185-9 (2005) (Pubitemid 41801114)
114. Kato, H., J. Takita, T. Miyazaki, M. Nakajima, Y. Fukai, N. Masuda, M. Fukuchi, R. Manda, H. Ojima, K. Tsukada & H. Kuwano: Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res, 22, 2635-9 (2002) (Pubitemid 36069291)
115. Cooper, R., S. Sarioglu, S. Sokmen, M. Fuzun, A. Kupelioglu, H. Valentine, I. B. Gorken, R. Airley & C. West: Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer, 89, 870-6 (2003) (Pubitemid 37175810)
116. Furudoi, A., S. Tanaka, K. Haruma, M. Yoshihara, K. Sumii, G. Kajiyama & F. Shimamoto: Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology, 60, 162-9 (2001) (Pubitemid 32245335)
117. Haber, R. S., A. Rathan, K. R. Weiser, A. Pritsker, S. H. Itzkowitz, C. Bodian, G. Slater, A. Weiss & D. E. Burstein: GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer, 83, 34-40 (1998) (Pubitemid 28299626)
118. Ozcan, A., M. S. Deveci, E. Oztas, M. Dede, M. C. Yenen, E. T. Korgun & O. Gunhan: Prognostic value of GLUT-1 expression in ovarian surface epithelial tumors: a morphometric study. Anal Quant Cytol Histol, 27, 181-6 (2005) (Pubitemid 41233493)
119. Schonberger, J., J. Ruschoff, D. Grimm, J. Marienhagen, P. Rummele, R. Meyringer, P. Kossmehl, F. Hofstaedter & C. Eilles: Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid, 12, 747-54 (2002)
120. Kim, Y. W., Y. K. Park, T. Y. Yoon & S. M. Lee: Expression of the GLUT1 glucose transporter in gallbladder carcinomas. Hepatogastroenterology, 49, 907-11 (2002)
121. Semenza, G. L., F. Agani, D. Feldser, N. Iyer, L. Kotch, E. Laughner & A. Yu: Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol, 475, 123-30 (2000) (Pubitemid 32197719)
122. Fillies, T., R. Werkmeister, P. J. van Diest, B. Brandt, U. Joos & H. Buerger: HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer, 5, 84 (2005)
123. Kyzas, P. A., D. Stefanou, A. Batistatou & N. J. Agnantis: Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study. Cancer Lett, 225, 297-304 (2005) (Pubitemid 40835878)
124. Birner, P., M. Schindl, A. Obermair, C. Plank, G. Breitenecker & G. Oberhuber: Overexpression of hypoxiainducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res, 60, 4693-6 (2000)
125. Haugland, H. K., V. Vukovic, M. Pintilie, A. W. Fyles, M. Milosevic, R. P. Hill & D. W. Hedley: Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys, 53, 854-61 (2002) (Pubitemid 34722629)
126. Ishikawa, H., H. Sakurai, M. Hasegawa, N. Mitsuhashi, M. Takahashi, N. Masuda, M. Nakajima, Y. Kitamoto, J. Saitoh & T. Nakano: Expression of hypoxicinducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 60, 513-21 (2004) (Pubitemid 39233471)
127. Burri, P., V. Djonov, D. M. Aebersold, K. Lindel, U. Studer, H. J. Altermatt, L. Mazzucchelli, R. H. Greiner & G. Gruber: Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys, 56, 494-501 (2003) (Pubitemid 36542909)
128. Bachtiary, B., M. Schindl, R. Potter, B. Dreier, T. H. Knocke, J. A. Hainfellner, R. Horvat & P. Birner: Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res, 9, 2234-40 (2003) (Pubitemid 36687648)
129. Schindl, M., S. F. Schoppmann, H. Samonigg, H. Hausmaninger, W. Kwasny, M. Gnant, R. Jakesz, E. Kubista, P. Birner & G. Oberhuber: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res, 8, 1831-7 (2002) (Pubitemid 34633742)
130. Bos, R., P. van der Groep, A. E. Greijer, A. Shvarts, S. Meijer, H. M. Pinedo, G. L. Semenza, P. J. van Diest & E. van der Wall: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer, 97, 1573-81 (2003) (Pubitemid 36297788)
131. Gruber, G., R. H. Greiner, R. Hlushchuk, D. M. Aebersold, H. J. Altermatt, G. Berclaz & V. Djonov: Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res, 6, R191-8 (2004)
132. Dales, J. P., S. Garcia, S. Meunier-Carpentier, L. Andrac-Meyer, O. Haddad, M. N. Lavaut, C. Allasia, P. Bonnier & C. Charpin: Overexpression of hypoxiainducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer, 116, 734-9 (2005) (Pubitemid 41099705)
133. Theodoropoulos, V. E., A. Lazaris, F. Sofras, I. Gerzelis, V. Tsoukala, I. Ghikonti, K. Manikas & I. Kastriotis: Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol, 46, 200-8 (2004) (Pubitemid 38902737)
134. Theodoropoulos, V. E., A. C. Lazaris, I. Kastriotis, C. Spiliadi, G. E. Theodoropoulos, V. Tsoukala, E. Patsouris & F. Sofras: Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int, 95, 425-31 (2005) (Pubitemid 40283138)
135. Matsuyama, T., K. Nakanishi, T. Hayashi, Y. Yoshizumi, S. Aiko, Y. Sugiura, T. Tanimoto, M. Uenoyama, Y. Ozeki & T. Maehara: Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci, 96, 176-82 (2005) (Pubitemid 40575919)
136. Kurokawa, T., M. Miyamoto, K. Kato, Y. Cho, Y. Kawarada, Y. Hida, T. Shinohara, T. Itoh, S. Okushiba, S. Kondo & H. Katoh: Overexpression of hypoxia-induciblefactor 1alpha (HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer, 89, 1042-7 (2003) (Pubitemid 37239209)
137. Irie, N., T. Matsuo & I. Nagata: Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol, 21, 1-6 (2004) (Pubitemid 38915175)
138. Shibaji, T., M. Nagao, N. Ikeda, H. Kanehiro, M. Hisanaga, S. Ko, A. Fukumoto & Y. Nakajima: Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res, 23, 4721-7 (2003) (Pubitemid 38173890)
139. Yoshimura, H., D. K. Dhar, H. Kohno, H. Kubota, T. Fujii, S. Ueda, S. Kinugasa, M. Tachibana & N. Nagasue: Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res, 10, 8554-60 (2004) (Pubitemid 40053424)
140. Lu, X. G., C. G. Xing, Y. Z. Feng, J. Chen & C. Deng: Clinical significance of immunohistochemical expression of hypoxia-inducible factor-1alpha as a prognostic marker in rectal adenocarcinoma. Clin Colorectal Cancer, 5, 350-3 (2006) (Pubitemid 43280065)
141. Lidgren, A., Y. Hedberg, K. Grankvist, T. Rasmuson, J. Vasko & B. Ljungberg: The expression of hypoxiainducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res, 11, 1129-35 (2005) (Pubitemid 40175762)
142. Urano, N., Y. Fujiwara, Y. Doki, M. Tsujie, H. Yamamoto, H. Miyata, S. Takiguchi, T. Yasuda, M. Yano & M. Monden: Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer, 9, 44-9 (2006)
143. Klabatsa, A., M. T. Sheaff, J. P. Steele, M. T. Evans, R. M. Rudd & D. A. Fennell: Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer, 51, 53-9 (2006) (Pubitemid 43088624)
144. Giatromanolaki, A., E. Sivridis, C. Kouskoukis, K. C. Gatter, A. L. Harris & M. I. Koukourakis: Hypoxiainducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res, 13, 493-501 (2003) (Pubitemid 37266952)
145. Felip, E., M. Taron, R. Rosell, P. Mendez, C. Queralt, M. S. Ronco, J. J. Sanchez, J. M. Sanchez, J. Maestre & J. Majo: Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-smallcell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery. Clin Lung Cancer, 6, 299-303 (2005) (Pubitemid 40852415)
146. Piert, M., H. J. Machulla, M. Picchio, G. Reischl, S. Ziegler, P. Kumar, H. J. Wester, R. Beck, A. J. McEwan, L. I. Wiebe & M. Schwaiger: Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med, 46, 106-13 (2005) (Pubitemid 43086004)